David Williamson
David Williamson, B.Pharm, M.Sc, Ph.D. is a Full Clinical Professor at the Faculty of Pharmacy of the Université de Montréal, as well as a Clinical Pharmacy Specialist at Sacré-Coeur Hospital in Montreal, Canada. He’s also an FRQ-S funded Clinical Scientist at the Sacré-Coeur Hospital Research Center. His research program focuses on the pharmacotherapy of sedation, agitation, delirium and pain in traumatic brain injury and in the ICU. His other research interests include drug safety and pharmacotherapeutic optimization in the critically ill.
Recent work
- Chan C, Burry L, Tse C, de Castro C, Wunsch H, Williamson D. Impact of ketamine analgosedation on outcomes in critically ill patients: Systematic review and meta-analysis. Ann Pharmacother 2022; ePub Jan 26th
- Bilodeau V, Saavedra Mitjans M, Frenette AJ, Burry L, Albert M, Bernard F, Williamson DR. Safety of dexmedetomidine for the control of agitation in critically ill traumatic brain injury patients: a descriptive study. J Clin Pharm Ther 2021;46:1020-26.
- Saavedra Mitjans M, David PM, Frenette AJ, Arbour C, Perreault MM, Williams V, Bernard F, Williamson DR. EXperienceS and aTtitudes towards Agitated behaviors in Tbi ICu patients (EXSTATIC): a protocol for an interprofessional mixed-method BMJ Open 2021; 11(7):e045816
- Williamson DR, Cherifa S, Saavedra Mitjans M, Arbour C, Frenette AJ, Charbonney E, Blais L, Burry LD, Mehta S, Bernard F. A pilot feasibility cohort study of agitated behaviors in critically traumatic brain injury patients. Pilot and feasibility Studies 2020;6:193.
- Williamson DR, Frenette AJ, Perreault MM, Burry LD, Charbonney E, Lamontagne F, Potvin MJ, Giguère JF, Mehta S, Bernard F. Pharmacological interventions for agitation and delirium in traumatic brain injury: a systematic review. BMJ Open 2019; 9;9(7):e029604.